{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:22:44Z","timestamp":1763018564271,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Portuguese Foundation for Science and Technology\/MCTES","award":["DL 57\/2016"],"award-info":[{"award-number":["DL 57\/2016"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","award":["DL 57\/2016"],"award-info":[{"award-number":["DL 57\/2016"]}]},{"name":"LILT 2020-21 Program and MAE-Call for Joint Project Proposals Italy-Brazil","award":["DL 57\/2016"],"award-info":[{"award-number":["DL 57\/2016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Cervical cancer (CC) is a disease that affects many women worldwide, especially in low-income countries. The human papilloma virus (HPV) is the main causative agent of this disease, with the E6 and E7 oncoproteins being responsible for the development and maintenance of transformed status. In addition, HPV is also responsible for the appearance of cervical intraepithelial neoplasia (CIN), a pre-neoplastic condition burdened by very high costs for its screening and therapy. So far, only prophylactic vaccines have been approved by regulatory agencies as a means of CC prevention. However, these vaccines cannot treat HPV-positive women. A search was conducted in several databases (PubMed, Scopus, Web of Science, and ClinicalTrials.gov) to systematically identify clinical trials involving therapeutic vaccines against CIN 3. Histopathological regression data, immunological parameters, safety, DNA clearance, and vaccine efficacy were considered from each selected study, and from the 102 articles found, 8 were selected based on the defined inclusion criteria. Histopathological regression from CIN 3 to CIN &lt; 1 was 22.1% (95% CI: 0.627\u20130.967; p-value = 0.024), showing a vaccine efficacy of 23.6% (95% CI; 0.666\u20130.876; p-value &lt; 0.001). DNA clearance was assessed, and the risk of persistent HPV DNA was 23.2% (95% CI: 0.667\u20130.885; p-value &lt; 0.001). Regarding immunological parameters, immune responses by specific T-HPV cells were more likely in vaccinated women (95% CI: 1.245\u20139.162; p-value = 0.017). In short, these studies favored the vaccine group over the placebo group. This work indicated that therapeutic vaccines are efficient in the treatment of CIN 3, even after accounting for publication bias.<\/jats:p>","DOI":"10.3390\/vaccines10091560","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:08:09Z","timestamp":1663718889000},"page":"1560","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Effectiveness of Therapeutic Vaccines for the Treatment of Cervical Intraepithelial Neoplasia 3: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"10","author":[{"given":"Cathy","family":"Ventura","sequence":"first","affiliation":[{"name":"CICS-UBI\u2013Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-6522","authenticated-orcid":false,"given":"\u00c2ngelo","family":"Lu\u00eds","sequence":"additional","affiliation":[{"name":"CICS-UBI\u2013Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"},{"name":"Grupo de Revis\u00f5es Sistem\u00e1ticas (GRUBI), Faculdade de Ci\u00eancias da Sa\u00fade, Universidade da Beira Interior, 6200-506 Covilh\u00e3, Portugal"}]},{"given":"Christiane P.","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, School of Pharmaceutical Sciences, S\u00e3o Paulo State University (UNESP), Campus Ville, Araraquara 14800-903, SP, Brazil"}]},{"given":"Aldo","family":"Venuti","sequence":"additional","affiliation":[{"name":"HPV-UNIT-UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}]},{"given":"Francesca","family":"Paolini","sequence":"additional","affiliation":[{"name":"HPV-UNIT-UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9068-4607","authenticated-orcid":false,"given":"Lu\u00edsa","family":"Pereira","sequence":"additional","affiliation":[{"name":"Grupo de Revis\u00f5es Sistem\u00e1ticas (GRUBI), Faculdade de Ci\u00eancias da Sa\u00fade, Universidade da Beira Interior, 6200-506 Covilh\u00e3, Portugal"},{"name":"CMA-UBI-Centro de Matem\u00e1tica e Aplica\u00e7\u00f5es, Universidade da Beira Interior, 6200-001 Covilh\u00e3, Portugal"},{"name":"C4-UBI, Cloud Computing Competence Centre, University of Beira Interior, 6200-284 Covilh\u00e3, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-7581","authenticated-orcid":false,"given":"\u00c2ngela","family":"Sousa","sequence":"additional","affiliation":[{"name":"CICS-UBI\u2013Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbadis.2007.12.005","article-title":"Viruses Associated with Human Cancer Margaret","volume":"1782","author":"Munger","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1126\/science.1659743","article-title":"Viruses in Human Cancers","volume":"254","year":"1991","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.drudis.2019.07.011","article-title":"Cervical Cancer and HPV Infection: Ongoing Therapeutic Research to Counteract the Action of E6 and E7 Oncoproteins","volume":"24","author":"Almeida","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_4","unstructured":"WHO (2020). Cervix Uteri Source: Globocan 2020. Int. Agency Res. Cancer, 419, 1\u20132."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3802\/jgo.2019.30.e37","article-title":"Incidence and Costs of Cervical Intraepithelial Neoplasia in the Korean Population","volume":"30","author":"Chang","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/LGT.0b013e3181ac05e9","article-title":"Incidence and Costs of Cervical Intraepithelial Neoplasia in a US Commercially Insured Population","volume":"14","author":"Henk","year":"2010","journal-title":"J. Low. Genit. Tract Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.3802\/jgo.2016.27.e21","article-title":"Clinical Significance of Human Papillomavirus Genotyping","volume":"27","author":"Choi","year":"2016","journal-title":"J. Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","article-title":"Biological and Clinical Aspects of HPV-Related Cancers","volume":"17","author":"Szymonowicz","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Moody, C.A. (2022). Regulation of the Innate Immune Response during the Human Papillomavirus Life Cycle. Viruses, 14.","DOI":"10.3390\/v14081797"},{"key":"ref_10","first-page":"165","article-title":"Human Papillomavirus and Cervical Cancer","volume":"16","author":"Sales","year":"2014","journal-title":"Cancer Inflamm. Mech. Chem. Biol. Clin. Asp."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Franconi, R., Massa, S., Paolini, F., Vici, P., and Venuti, A. (2020). Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers. Cancers, 12.","DOI":"10.3390\/cancers12113101"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mrrev.2016.08.001","article-title":"Molecular Mechanisms Underlying Human Papillomavirus E6 and E7 Oncoprotein-Induced Cell Transformation","volume":"772","author":"Mittal","year":"2017","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Ram\u00edrez, I., Carrillo-Garc\u00eda, A., Contreras-Paredes, A., Ortiz-S\u00e1nchez, E., Cruz-Gregorio, A., and Lizano, M. (2018). Regulation of Cellular Metabolism by High-Risk Human Papillomaviruses. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071839"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","article-title":"The HPV E6\/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets","volume":"26","author":"Bossler","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13174","DOI":"10.1128\/JVI.02172-12","article-title":"Comprehensive Analysis of Host Cellular Interactions with Human Papillomavirus E6 Proteins Identifies New E6 Binding Partners and Reflects Viral Diversity","volume":"86","author":"White","year":"2012","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E260","DOI":"10.1073\/pnas.1116776109","article-title":"Systematic Identification of Interactions between Host Cell Proteins and E7 Oncoproteins from Diverse Human Papillomaviruses","volume":"109","author":"White","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gomes, D., Silvestre, S., Duarte, A.P., Venuti, A., Soares, C.P., Passarinha, L., and Sousa, \u00c2. (2021). In Silico Approaches: A Way to Unveil Novel Therapeutic Drugs for Cervical Cancer Management. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080741"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Bello, J.O., Carrillo-Garc\u00eda, A., and Lizano, M. (2022). Epidemiology and Molecular Biology of HPV Variants in Cervical Cancer: The State of the Art in Mexico. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158566"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/jcp.2005.036426","article-title":"Our Approach to Squamous Intraepithelial Lesions of the Uterine Cervix","volume":"60","author":"Kalof","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide Burden of Cancer Attributable to HPV by Site, Country and HPV Type","volume":"141","author":"Plummer","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/hum.2017.197","article-title":"Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases","volume":"29","author":"Cheng","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Guo, C., Manjili, M.H., Subjeck, J.R., Sarkar, D., Fisher, P.B., and Wang, X.Y. (2013). Therapeutic Cancer Vaccines. Past, Present, and Future, Academic Press Inc.","DOI":"10.1016\/B978-0-12-407190-2.00007-1"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Boilesen, D.R., Nielsen, K.N., and Holst, P.J. (2021). Novel Antigenic Targets of Hpv Therapeutic Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9111262"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting Immune Response with Therapeutic Vaccines in Premalignant Lesions and Cervical Cancer: Hope or Reality from Clinical Studies","volume":"15","author":"Vici","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","article-title":"The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease","volume":"11","author":"Garbuglia","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 Explanation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Borenstein, M., Hedges, L.V., Higgins, J.P.T., and Rothstein, H.R. (2009). Introduction to Meta-Analysis, John Wiley & Sons, Ltd.","DOI":"10.1002\/9780470743386"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Light, R.J., and Pillemer, D.B. (1984). Summing Up: The Science of Reviewing Research, Harvard University Press.","DOI":"10.4159\/9780674040243"},{"key":"ref_31","unstructured":"Cooper, H.M., Valentine, J.C., and Hedges, L.V. (2009). Handbook of Research Synthesis and Meta-Analysis, Russel Sage Foundation. [2nd ed.]."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in Meta-Analysis Detected by a Simple, Graphical Test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"key":"ref_33","first-page":"89","article-title":"A Nonparametric \u201cTrim and Fill\u201d Method of Accounting for Publication Bias in Meta-Analysis","volume":"95","author":"Duval","year":"2000","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and Fill: A Simple Funnel-Plot-Based Method","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, Efficacy, and Immunogenicity of VGX-3100, a Therapeutic Synthetic DNA Vaccine Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins for Cervical Intraepithelial Neoplasia 2\/3: A Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial","volume":"386","author":"Trimble","year":"2016","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Karimi-Zarchi, M., Allahqoli, L., Nehmati, A., Kashi, A.M., Taghipour-Zahir, S., and Alkatout, I. (2020). Can the Prophylactic Quadrivalent HPV Vaccine Be Used as a Therapeutic Agent in Women with CIN? A Randomized Trial. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-8371-z"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2019.03.250","article-title":"The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 years of Follow-Up","volume":"153","author":"Harper","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination Trial with HPV16 L1E7 Chimeric Virus-like Particles in Women Suffering from High Grade Cervical Intraepithelial Neoplasia (CIN 2\/3)","volume":"121","author":"Kaufmann","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ikeda, Y., Adachi, K., Tomio, K., Eguchi-Kojima, S., Tsuruga, T., Uchino-Mori, M., Taguchi, A., Komatsu, A., Nagamatsu, T., and Oda, K. (2021). A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing Lactobacillus, GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2). Vaccines, 9.","DOI":"10.3390\/vaccines9040329"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2004.05.013","article-title":"Phase 1 Study of HPV16-Specific Immunotherapy with E6E7 Fusion Protein and ISCOMATRIXTM Adjuvant in Women with Cervical Intraepithelial Neoplasia","volume":"23","author":"Frazer","year":"2004","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial","volume":"103","author":"Garcia","year":"2004","journal-title":"Obstet. Gynecol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cellimm.2011.04.005","article-title":"Immunization with a Poly (Lactide Co-Glycolide) Encapsulated Plasmid DNA Expressing Antigenic Regions of HPV 16 and 18 Results in an Increase in the Precursor Frequency of T Cells That Respond to Epitopes from HPV 16, 18, 6 and 11","volume":"270","author":"Matijevic","year":"2011","journal-title":"Cell. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major Findings and Recent Advances in Virus\u2013like Particle (VLP)-Based Vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/bit.24493","article-title":"Vaccine Process Technology","volume":"109","author":"Josefsberg","year":"2012","journal-title":"Biotechnol. Bioeng."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/ijc.25940","article-title":"Impact of an HPV6\/11\/16\/18 L1 Virus-like Particle Vaccine on Progression to Cervical Intraepithelial Neoplasia in Seropositive Women with HPV16\/18 Infection","volume":"129","author":"Haupt","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/ijc.22035","article-title":"Oral Administration of Human Papillomavirus Type 16 E7 Displayed on Lactobacillus Casei Induces E7-Specific Antitumor Effects in C57\/BL6 Mice","volume":"119","author":"Poo","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2221-1691(15)30366-X","article-title":"The Past, Current and Future Trends in DNA Vaccine Immunisations","volume":"5","author":"Hasson","year":"2015","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular Mechanisms for Enhanced DNA Vaccine Immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nri2173","article-title":"Dendritic-Cell Immunotherapy: From Ex Vivo Loading to in Vivo Targeting","volume":"7","author":"Tacken","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.drudis.2021.06.008","article-title":"Methods to Improve the Immunogenicity of Plasmid DNA Vaccines","volume":"26","author":"Neves","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/21691401.2014.971805","article-title":"Applications of Nanoparticle Systems in Gene Delivery and Gene Therapy","volume":"44","author":"Kafshdooz","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"627932","DOI":"10.3389\/fimmu.2021.627932","article-title":"Cancer Vaccines, Adjuvants, and Delivery Systems","volume":"12","author":"Paston","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/17425247.5.6.703","article-title":"Mannose-Targeted Systems for the Delivery of Therapeutics","volume":"5","author":"Irache","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Akhatova, A., Chan, C.K., Azizan, A., and Aimagambetova, G. (2022). The Efficacy of Therapeutic DNA Vaccines Expressing the Human Papillomavirus E6 and E7 Oncoproteins for Treatment of Cervical Cancer: Systematic Review. Vaccines, 10.","DOI":"10.3390\/vaccines10010053"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Henere, C., Torn\u00e9, A., Llupi\u00e0, A., Aldea, M., Mart\u00ed, C., Glickman, A., Saco, A., Marimon, L., Manzotti, C., and Rakislova, N. (2022). HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions. Vaccines, 10.","DOI":"10.3390\/vaccines10060887"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e070135","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of Human Papillomavirus (HPV) Vaccination on HPV Infection and Recurrence of HPV Related Disease after Local Surgical Treatment: Systematic Review and Meta-Analysis","volume":"378","author":"Kechagias","year":"2022","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tang, J., Li, M., Zhao, C., Shen, D., Liu, L., Zhang, X., and Wei, L. (2022). Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials. Viruses, 14.","DOI":"10.3390\/v14020239"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1560\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:34:08Z","timestamp":1760142848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["vaccines10091560"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10091560","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}